Pioglitazone and Losartan Provides Additional Renoprotection

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II receptor antagonist losartan reduced the levels of proteinuria.Whether Combination therapy with pioglitazone and losartan provides additional renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Losartan; Pioglitazone

Criteria

Inclusion Criteria:

• Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L

• 2h plasma glucose level of 7.5-13 mmol/L

• serum creatinine values between 190 and 660umol/L

• Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is >150mg

• Informed consent

Exclusion Criteria:

• Type1 diabetes or nondiabetic renal disease

• abnormal liver function

• heart dysfunction